Whitehawk Therapeutics (WHWK) EBIT Margin: 2018-2025
Historic EBIT Margin for Whitehawk Therapeutics (WHWK) over the last 4 years, with Mar 2025 value amounting to -212.99%.
- Whitehawk Therapeutics' EBIT Margin rose 15152.00% to -212.99% in Q1 2025 from the same period last year, while for Mar 2025 it was -227.41%, marking a year-over-year increase of 8559.00%. This contributed to the annual value of -259.62% for FY2024, which is 3574.00% up from last year.
- Whitehawk Therapeutics' EBIT Margin amounted to -212.99% in Q1 2025, which was up 18.63% from -261.76% recorded in Q4 2024.
- Whitehawk Therapeutics' 5-year EBIT Margin high stood at 55,612.10% for Q3 2021, and its period low was -3,405.83% during Q1 2021.
- In the last 3 years, Whitehawk Therapeutics' EBIT Margin had a median value of -280.02% in 2023 and averaged -273.21%.
- As far as peak fluctuations go, Whitehawk Therapeutics' EBIT Margin skyrocketed by 5,676,492bps in 2021, and later plummeted by 5,596,631bps in 2022.
- Over the past 5 years, Whitehawk Therapeutics' EBIT Margin (Quarterly) stood at -113.89% in 2021, then slumped by 18,211bps to -296.00% in 2022, then soared by 1,598bps to -280.02% in 2023, then soared by 1,826bps to -261.76% in 2024, then spiked by 15,152bps to -212.99% in 2025.
- Its EBIT Margin was -212.99% in Q1 2025, compared to -261.76% in Q4 2024 and -185.98% in Q3 2024.